Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Polygenic risk score and 20-year prostate cancer-specific mortality and survival

Plym, Anna LU ; Wang, Anqi ; Stopsack, Konrad H. ; Zhang, Yiwen ; Baras, Aris ; Drake, Isabel LU ; Clements, Mark ; Penney, Kathryn L. ; Giovannucci, Edward and Kibel, Adam S. , et al. (2026) In Communications medicine 6(1).
Abstract

Background: Polygenic risk scores (PRSs) strongly discriminate for prostate cancer risk at the population level. The role of these genetic scores in determining prostate cancer survival is unclear, potentially due to methodological issues. Methods: We included 19,607 men from the Malmö Diet and Cancer Study (MDCS) and the Health Professionals Follow-up Study (HPFS) and analyzed 20-year incidence and mortality (from full cohort analyses) and survival (from case-only analyses) according to a 451-variant PRS. For most of the men included, early access to prostate-specific antigen (PSA) testing was limited. Results: In full cohort analyses, a PRS at or above the median (vs. below the median) shows a strong association with prostate cancer... (More)

Background: Polygenic risk scores (PRSs) strongly discriminate for prostate cancer risk at the population level. The role of these genetic scores in determining prostate cancer survival is unclear, potentially due to methodological issues. Methods: We included 19,607 men from the Malmö Diet and Cancer Study (MDCS) and the Health Professionals Follow-up Study (HPFS) and analyzed 20-year incidence and mortality (from full cohort analyses) and survival (from case-only analyses) according to a 451-variant PRS. For most of the men included, early access to prostate-specific antigen (PSA) testing was limited. Results: In full cohort analyses, a PRS at or above the median (vs. below the median) shows a strong association with prostate cancer incidence (hazard ratio (HR) 3.02, 95% CI 2.78-3.28) and, somewhat stronger, with prostate cancer mortality (HR 3.26, 95% CI 2.63-4.04). As expected, case-only survival analyses of prostate cancer death show a similar direction (HR 1.21, 95% CI 0.98-1.50), which becomes stronger when excluding variants linked to PSA (HR 1.25, 95% CI, 1.01-1.54), in particular in the age group 65-74 years at diagnosis (HR 1.72, 95% CI 1.21-2.45). In the other age groups, HRs are close to or below 1. This indicates that standard case-only survival estimates may not accurately reflect risk across age, consistent with age-dependent selection mechanisms, and further points to an influence from disease detection. Conclusions: Overall, these findings support that inherited genetic risk captured by the 451-variant PRS may have an influence on prostate cancer survival.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Communications medicine
volume
6
issue
1
article number
243
publisher
Nature Publishing Group
external identifiers
  • pmid:42032305
  • scopus:105036697339
ISSN
2730-664X
DOI
10.1038/s43856-026-01603-9
language
English
LU publication?
yes
id
7e457965-4f3d-4950-a9a2-69c1b16eee33
date added to LUP
2026-06-23 12:03:54
date last changed
2026-09-02 23:57:57
@article{7e457965-4f3d-4950-a9a2-69c1b16eee33,
  abstract     = {{<p>Background: Polygenic risk scores (PRSs) strongly discriminate for prostate cancer risk at the population level. The role of these genetic scores in determining prostate cancer survival is unclear, potentially due to methodological issues. Methods: We included 19,607 men from the Malmö Diet and Cancer Study (MDCS) and the Health Professionals Follow-up Study (HPFS) and analyzed 20-year incidence and mortality (from full cohort analyses) and survival (from case-only analyses) according to a 451-variant PRS. For most of the men included, early access to prostate-specific antigen (PSA) testing was limited. Results: In full cohort analyses, a PRS at or above the median (vs. below the median) shows a strong association with prostate cancer incidence (hazard ratio (HR) 3.02, 95% CI 2.78-3.28) and, somewhat stronger, with prostate cancer mortality (HR 3.26, 95% CI 2.63-4.04). As expected, case-only survival analyses of prostate cancer death show a similar direction (HR 1.21, 95% CI 0.98-1.50), which becomes stronger when excluding variants linked to PSA (HR 1.25, 95% CI, 1.01-1.54), in particular in the age group 65-74 years at diagnosis (HR 1.72, 95% CI 1.21-2.45). In the other age groups, HRs are close to or below 1. This indicates that standard case-only survival estimates may not accurately reflect risk across age, consistent with age-dependent selection mechanisms, and further points to an influence from disease detection. Conclusions: Overall, these findings support that inherited genetic risk captured by the 451-variant PRS may have an influence on prostate cancer survival.</p>}},
  author       = {{Plym, Anna and Wang, Anqi and Stopsack, Konrad H. and Zhang, Yiwen and Baras, Aris and Drake, Isabel and Clements, Mark and Penney, Kathryn L. and Giovannucci, Edward and Kibel, Adam S. and Mucci, Lorelei A. and Wiklund, Fredrik}},
  issn         = {{2730-664X}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Communications medicine}},
  title        = {{Polygenic risk score and 20-year prostate cancer-specific mortality and survival}},
  url          = {{http://dx.doi.org/10.1038/s43856-026-01603-9}},
  doi          = {{10.1038/s43856-026-01603-9}},
  volume       = {{6}},
  year         = {{2026}},
}